Testing the lab-developed brain cancer cells, researchers at Johns Hopkins Medicine have included to prove that lack of particular tiny molecules that silence specific genes is associated to the growth and development of pediatric brain tumors dubbed as low-grade gliomas.
A report of the results was posted in Scientific Reports, and supports the thought of elevating the levels of microRNAs as a possible means of curing these tumors.
An expected 1,600 cases of PLGGs (pediatric low-grade gliomas) are detected each year in the U.S., and the huge majority of these slow-developing tumors are curable and treatable mainly by surgical elimination, even though in some cases operation has the capability to damage essential nearby brain tissue, relying on location of tumor. Unlike high-level glioblastomas, PLGGs mostly impact young adults and school-age kids.
“It has long been recognized that microRNAs has significance in controlling different tumor characteristics such as development,” claimed the study’s senior author, Fausto Rodriguez, to the media in an interview.
Speaking of gene, after years of hard work, scientists have made a breakthrough in removing the HIV infection from the human affected T cells incorporated into the mice models.
Dr. Wenhui Hu from the Temple University and his team comprising of Laura H. Carnell, Won-Bin Young, and Kamel Khalili are the brainchildren behind this new discovery. The researchers have been able to excise the HIV-1 provirus using the gene editing technology named “CRISPR/Cas9.” A provirus is nothing but an inactive type of the virus, which normally occurs when the virus is incorporated into the genes present in a cell. In case of HIV, the host cell is the CD4 cell into the DNA of which the virus integrates itself and further undergoes replication as the CD4 cells multiply.
The research team carried out the study by injecting the HIV-1 provirus into the three humanized mice models that had human immune cells included in them.